// App-Quantinova.ai

PB0593 : Increased Percentage of Extended Aα Chain Fibrinogen (αE) in COVID-19 Patients

Researchers

Presenter

  • J. de Vries

Principal Investigators

  • C. Visser

  • E. van Nood

  • M. Kruip

  • M. de Maat

Medical Centers

  • Fibriant B.V., Leiden, Zuid-Holland, Netherlands

  • Department of Medical Microbiology and Infectious Diseases & Department of Internal Medicine, Erasmus MC, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands, Rotterdam, Zuid-Holland, Netherlands

  • Department of Internal Medicine & Department of Viroscience, Erasmus MC, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands, Rotterdam, Zuid-Holland, Netherlands

  • Department of Internal Medicine & Department of Viroscience, Erasmus MC, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands, Rotterdam, Zuid-Holland, Netherlands

  • Department of Adult Intensive Care, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands, Rotterdam, Zuid-Holland, Netherlands

  • Department of Hepatology, Erasmus MC, University Medical Center Rotterdam, the Netherlands, Rotterdam, Netherlands

Locations

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Pulmonary/Respiratory Diseases

  • Infectious Diseases (ID)

  • Blood/haematological Diseases

Disease

  • Venous thrombosis

  • Coronavirus disease

Biomarkers

  • Fibrinogen

Drug/Treatment

  • Fibrinogen (IV)

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved